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Abstract
Heparanase-1 (HPR1), an endoglycosidase that specifically degrades heparan sulfate (HS) proteoglycans, is over-
expressed in a variety of malignancies. Our present study sought to determine whether oncogene BRAF and RAS
mutations lead to increased HPR1 expression. Reverse transcription–polymerase chain reaction analysis revealed
that HPR1 gene expression was increased in HEK293 cells transiently transfected with a mutant BRAF or RAS gene.
Flow cytometric analysis revealed that B-Raf activation led to loss of the cell surface HS, which could be blocked by
two HPR1 inhibitors: heparin and PI-88. Cotransfection of a BRAF or RAS mutant gene with HPR1 promoter–driven
luciferase reporters increased luciferase reporter gene expression in HEK293 cells. Knockdown of BRAF expression in
a BRAF-mutated KAT-10 tumor cell line led to the suppression of HPR1 gene expression, subsequently leading to
increased cell surface HS levels. Truncational and mutational analyses of the HPR1 promoter revealed that the Ets-
relevant elements in the HPR1 promoter were critical for BRAF activation–induced HPR1 expression. Luciferase
reporter gene expression driven by a four-copy GA binding protein (GABP) binding site was significantly lower in
BRAF siRNA–transfected KAT-10 cells than in the control siRNA–transfected cells. We further showed that BRAF
knockdown led to suppression of the expression of the GABPβ, an Ets family transcription factor involved in regu-
lating HPR1 promoter activity. Taken together, our study suggests that B-Raf kinase activation plays an important
role in regulating HPR1 expression. Increased HPR1 expression may contribute to the aggressive behavior of BRAF-
mutated cancer.
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Introduction
Heparanase-1 (HPR1) is an endoglycosidase that specifically degrades
heparan sulfate (HS) proteoglycans (HSPGs) [1–4]. HSPGs are heavily
present on the cell surface and in the extracellular matrix (ECM) and
the basement membrane (BM). HPR1 is overexpressed in a variety of
malignancies [1–4]. Breakdown ofHSPGs in the BMand ECM leads to
the release of many growth factors such as fibroblast growth factor and
vascular endothelial growth factor that are trapped in the tumor stroma.
These growth factors can promote tumor angiogenesis by stimulating
endothelial cell proliferation and migration. In addition, breakdown
of the BM and ECM allows tumor cells to invade locally or metastasize
to a distant site. Recent studies have shown that HPR1 exerts its many
biologic functions independent of its enzymatic activity. For example,
HPR1 can enhance cell adhesion [5,6], induce vascular endothelial
growth factor expression [7], induce tumor and endothelial cell migra-
tion, and induce Akt, p38, and Src phosphorylation [7,8]. HPR1 can
induce epidermal growth factor (EGF) receptor phosphorylation and
stimulate tumor cell proliferation and growth in an enzymatic activity–
independent manner [9]. A conservative, hydrophobic C-terminus do-
main of HPR1 has been recently identified to mediate these diverse
biologic functions [10,11]. HPR1 C-terminus functions as a ligand to
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bind two potential unknown receptors (a 130- and a 170-kDa protein)
to activate the phosphatidylinositol 3-kinase pathway [11]. HPR1 may
exert its tumor-promoting effect independent of its enzymatic activity.
Molecular mechanisms of HPR1 overexpression in a variety of can-
cers remain poorly understood. We and others have previously charac-
terized the HPR1 promoter [12,13]. Sequence analysis revealed that the
TATA-less, GC-rich promoter of the HPR1 gene belongs to the family
of housekeeping genes. Three Sp1 sites and four Ets relevant elements
(ERE) for two GA binding protein (GABP) binding sites (Figure 7)
are located in a 0.3-kb proximal promoter region [13]. GABP and
Sp1/Sp3 are two transcription factors that regulate HPR1 basal pro-
moter activity [13]. Later studies demonstrated that Egr-1 is involved
in HPR1 gene expression in T cells stimulated by PMA plus ionomycin
and in tumor cells [14–16]. Recent studies suggest that increased HPR1
expression in bladder and prostate cancers is largely mediated by HPR1
promoter hypomethylation and Egr-1 overexpression and hyperactiva-
tion [16,17] (Figure 7). Because tumor suppressor p53 can negatively
regulateHPR1 gene expression [18], p53 gene mutation may also con-
tribute to increased HPR1 expression in a variety of tumors. It is not
clear whether oncogene mutation and activation can lead to increased
HPR1 expression.
BRAF is an oncogene that is frequently mutated in a variety of ma-
lignancies, with the highest frequencies in melanomas and thyroid
cancers [19]. We have previously characterized HPR1 expression and
BRAF gene mutation in thyroid cancer [20,21]. Interestingly, we found
that HPR1 is expressed at relatively low levels in WRO82 and KAT-18
cells, two thyroid tumor cell lines with wild-type BRAF, compared with
that in several BRAF mutant tumor cell lines. We hypothesize that
BRAF and RAS mutations may be responsible for increased HPR1 ex-
pression in cancer. Here we report that HPR1 gene expression was in-
duced in the cells transfected with mutant BRAF and RAS genes and
that knockdown of BRAF led to decreasedHPR1 expression. GABP, an
Ets family transcription factor, was responsible for BRAF mutation–
induced HPR1 expression.
Materials and Methods
Plasmids and Cell Lines
pEF6 empty vector, and the vector encoding a wild-type BRAF
(pEF6/BRAF), mutant V600E BRAF (pEF6/BRAFV600E), or mutant
G12VHRAS (pEF6/HRASG12V), have been previously described [22].
Luciferase reporter constructs driven by various truncated or mutated
HPR1 promoters (Figure 5A) and by a four-copy of the GABP binding
site derived from human FAS gene have been previously described
[13,23]. KAT-10 cells transfected with a small interference (si)RNA
vector IMG800 or the vector encoding a BRAF siRNA have been
previously reported [24]. KAT-10 cells were previously considered a
tumor cell line of thyroid origin but were recently verified as identical
to HT29, a human colon cancer cell line [25]. KAT-10 cells were grown
in complete RPMI 1640 medium containing 10% fetal bovine serum
and 500 μg/ml G418. HEK293, a human kidney embryonic epithelial
cell line, was purchased from the American Tissue Culture Collection
(Manassas, VA). HEK293 cells were grown in minimum essential me-
dium containing 10% fetal bovine serum, nonessential amino acids,
sodium pyruvate, and HEPES buffer.
Luciferase Reporter Gene Expression
HEK293 cells seeded in a 24-well plate were transfected with pGL3/
basic, a 0.7-kb or 3.5-kbHPR1 promoter–driven luciferase reporter gene
plus pEF6 empty vector, pEF6/BRAF, pEF6/BRAFV600E, and pEF6/
HRASG12V by using FuGENE6 (Roche Applied Science, Indianapolis,
IN) following the manufacturer’s instructions (Figure 1B). An internal
control plasmid, pCMV/SPORT, which encodes a β-galactosidase gene,
was included in the transfection mixture. Control or BRAF siRNA–
transfected KAT-10 cells were similarly transfected with the luciferase
reporter gene driven by a 0.3-, 0.7-, or 3.5-kb HPR1 promoter (pGL3/
HPR-0.3, pGL3/HPR1-0.7, or pGL3/HPR-3.5; Figure 4), by a 0.3-kb
HPR1 promoter with various mutated ERE sites (Figure 5, A and B),
or by a four-copy GABP binding site (Figure 5C). Luciferase reporter
gene without a HPR1 promoter (pGL3/Basic) was included as a nega-
tive control. After incubating for 48 hours, cells were harvested and
analyzed for luciferase activity by using the luciferin substrate and read-
ing in a TECAN plate reader (Phenix Research Products, Hayward,
CA). The relative light unit in each sample was normalized against the
β-galactosidase activity measured by a colorimetric assay as previously
reported [26]. The means ± SDs of the data in triplicate from one ex-
periment are presented. The experiment was repeated at least once with
similar results.
Flow Cytometric Analysis
HEK293 cells were seeded in six-well plates. On 40% confluence,
the cells were transfected with pEF6 empty vector, pEF6/BRAF, pEF6/
BRAFV600E, and pEF6/HRASG12V. After incubating for 24 hours, the
cells were left untreated or treated with two HPR1 inhibitors, heparin
or PI-88 (50 μg/ml). After incubating for another 24 hours, the cells
were harvested and used for the preparation of single cell suspensions.
Single cell suspensions of HEK293 and KAT-10 cells were incubated
with an anti-HS mAb (0.5 μg/sample; clone HepSS; Seikagaku Corp,
Chuo-ku, Tokyo, Japan) or mouse immunoglobulin M (IgM) as an
isotype control for 30 minutes at 4°C, followed by incubation with
fluorescein isothiocyanate–labeled goat antimouse IgM (5 μl/sample)
for 30 minutes at 4°C. To increase the fluorescence intensity, the cells
were further stained with a fluorescein isothiocyanate–labeled rabbit
antigoat IgG (5 μl/sample) for 30minutes at 4°C. Cell surface HS levels
were analyzed by fluorescence-activated cell sorter (FACS) in a Becton
Dickinson flow cytometer.
HPR1 Activity Assay
HPR1 activity in cell lysates was measured by using a novel ELISA as
previously described [27–30].HPR1 activity in cell lysates was calculated
based on a standard curve of serially diluted purified platelet HPR1
(starting at 1:200) [31] at a concentration of 1 μl of HPR1 with the
activity of degrading 0.133 μg of heparan sulfate per hour at 37°C in
HPR1 buffer. HPR1 activity was designated as per 100 U capable of
degrading 1 ng of heparan sulfate at 37°C per hour in HPR1 buffer.
Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted from control or BRAF siRNA–transfected
KAT-10 cells andHEK293 cells transfected with the pEF6 empty vector,
pEF6/BRAF, pEF6/BRAFV600E, and pEF6/HRASG12V using TRIzol
(Invitrogen, Camarillo, CA) and quantified in a spectrophotometer
by ultraviolet absorption. Complementary DNA was synthesized by
using AMVreverse transcriptase with 500 ng of total RNA and oligo(dT)
priming. Polymerase chain reaction (PCR) was conducted by using Taq
DNA polymerase (Invitrogen) with a pair of primers listed in Table 1.
The PCR conditions for amplifying HPR1 and GAPDH are an initial
denaturation of 2 minutes at 94°C, followed by 32 cycles of denaturation
for 45 seconds at 94°C, annealing for 1minute at 55°C, and extension for
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1minute at 72°C. PCR products were separated on a 1.5% agarose gel by
electrophoresis and visualized by ethidium bromide staining. HPR1,
BRAF, and GABPα and β expressions in KAT-10 cells were also quanti-
fied by real-time reverse transcription (RT)–PCR with primers listed in
Table 1. Complementary DNAwas synthesized as above used for ampli-
fying these genes in triplicate after a 1:10 dilution. PCR in a 25-μl volume
was conducted by using cyber green mixture and ran initially at 50°C for
2 minutes and at 95°C for 10 minutes followed by 40 cycles of (95°C
for 15 seconds and 60°C for 1 minute). PCR was analyzed on Applied
Biosystems 7300 (Foster City, CA). The relative C t value was cal-
culated according to the standard formula 2Δ/ΔC t (Δ/ΔC t = ΔC t value
of sample − ΔC t value of control). ΔC t value of each sample is the
C t value for BRAF siRNA–transfected cells normalized to18S ribo-
somal RNA (rRNA), whereas ΔC t value of the control is the C t value
for control siRNA–transfected cells normalized to 18S rRNA. The rel-
ative expression of these genes from one representative of two or more
independent experiments with similar results is presented.
Western Blot
KAT-10 cells were lysed inNP-40 lysis buffer (50 mMTris-HCl [pH
8.0], 150 mM NaCl, 1% NP-40, 5 mM EDTA, 10 μg/ml aprotinin,
10 μg/ml leupeptinin, and 1 mM phenylmethylsulfonyl fluoride). Cell
lysates were incubated on ice for 30 minutes and then spun down at
15,000 rpm for 15 minutes at 4°C. After electrophoresis and transfer
to nitrocellulose membranes, B-Raf, Sp1, Sp3, Egr-1, phorspho-ERK,
ERK, and GABPα and β were detected by their specific antibodies
followed by horseradish peroxidase–conjugated goat antimouse or
rabbit IgG and SuperSignal Western Pico enhanced chemilumines-
cence substrate (Pierce Chemical Co, Rockford, IL). These antibodies
include rabbit anti–B-Raf, Sp1, Sp3, Egr-1 IgG (Santa Cruz Biotechnol-
ogy, Inc, SanDiego, CA), rabbit anti–phospho ERK and ERK IgG (Cell
Signaling Technology, Danvers, MA), and rabbit anti-GABPα and β
antisera (kindly provided by Dr. U. A. Rapp, University of Würzburg,
Würzburg, Germany).
Immunofluorescence Staining of GABPα and β
KAT-10 cells grown on coverslips were washed three times with cold
PBS and fixed with methanol at −20°C for 5 minutes. Coverslips were
blocked with 5% normal goat serum for 30 minutes at room tempera-
ture. GABPα and β were detected by rabbit anti-GABPα or β antisera,
followed by fluorescein-conjugated goat antirabbit IgG. The coverslips
were mounted with 50% glycerin in PBS containing antifade reagent
1,4-diazabicyclo[2.2.2]octane (25 mg/ml) and 4,6-diamidino-2-
phenylindole (0.5mg/ml; SigmaChemical Co, St Louis,MO).GABPα
or β expression was examined under a fluorescence microscope. The
pictures were taken with a digital camera attached in an Olympus
BX41TF fluorescence microscope (Leeds Precision Instruments, Inc,
Minneapolis, MN).
Statistical Analysis
The differences in the expression of HPR1, BRAF, GABPα or β, and
HPR1 activity were statistically analyzed by using an unpaired Student
t test. P < .05 was considered statistically significant.
Results
Induction of HPR1 Expression by Activation of B-Raf Kinase
We first tested if RAS and BRAF gene mutations led to increased
HPR1 gene expression. HPR1 messenger RNA (mRNA) levels in
HEK293 cells transiently transfected with the pEF6 empty vector or
the vector encoding wild-type BRAF, BRAFV600E, or RASG12V were
analyzed by semiquantitative RT-PCR. As shown in Figure 1A, HPR1
mRNA was undetectable in HEK293 cells transfected with the pEF6
empty vector or the vector encoding wild-type BRAF but was induced
in the cells transfected with a constitutively active BRAFV600Emutant or
HRASG12V genes. A 0.7-kb HPR1 promoter–driven luciferase reporter
gene expression was dramatically increased in HEK293 cells cotrans-
fected with pEF6/BRAFV600E or pEF6/HRASG12V but not in the cells
cotransfected with pEF6 or pEF6/BRAF (Figure 1B). Expression of a
3.5-kb HPR1 promoter–driven luciferase reporter gene was also slightly
increased in HEK293 cells cotransfected with the pEF6 encoding
wild-type BRAF but was dramatically increased in the cells cotrans-
fected by pEF6/BRAFV600E and pEF6/HRASG12V. Induction of HPR1
promoter–driven luciferase expression by HRASV12 was less potent
than BRAFV600E mutant, although the former is much more potent
in activating the MAP kinase pathway [22].
B-Raf Kinase Activation Leads to Accelerated Cell
Surface HS Degradation
Wenext tested whether increasedHPR1 expression bymutant BRAF
or HRAS leads to the degradation of HSPG. HEK293 cells were
transiently transfected with pEF6, pEF6/BRAF, pEF6/BRAFV600E, or
pEF6/HRASV12. As shown in Figure 2A, the cell surface HS expression
was abrogated in the cells transfected with mutant BRAF or RAS gene
but not in those transfectedwith the pEF6 empty vector or pEF6/BRAF
(Figure 2A). Two HPR1 inhibitors, PI-88 or heparin (50 μg/ml each),
were able to restore the cell surface HS levels of HEK293 cells trans-
fected with pEF6/BRAFV600E or pEF6/HRASG12V (Figure 2B). Similar
results were obtained in 10/56A cells, immortalized human glomerular
epithelial cells (data not shown). These observations suggest that down-
regulation of HS expression in transfected cells is due to increased deg-
radation of HS by HPR1.
Inhibition of HPR1 Gene Expression in a BRAF-Suppressed
Tumor Cell Line
To verify that B-Raf kinase activation plays a critical role in inducing
HPR1 gene expression, we tested if BRAF knockdown leads to decreased
Table 1. Primers Used to Amplify HPR1, BRAF, GABPα, GABPβ, GAPDH, and 18S rRNA.
Gene Size (bp) Forward Reverse
HPR1 587 5′-TTCGATCCCAAGAAGG-AATCAAC-3′ 5′GTAGTGATGCCATGTAACTGAAT-C-3′
GAPDH 527 5′TGAAGGTCGGAGTCAACGGATTTGGTC-3′ 5′ATGGACTGTGGTCATGAGTCCTTCCACG-3′
HPR1 86 5′-GCTAGAGCTCTCGACTCTC-3′ 5′-GCAGGCTTCGAGCGCAGC-3′
BRAF 199 5′-TTGAACACCACCCAATACCA-3′ 5′-GTCTCGTTGCCCAAATTGAT-3′
GABPα 116 5′-ACGATGGGGACATGATTTGT-3′ 5′-TTCTGTGACCAAACGGTTCA-3′
GABPβ 121 5′-GTGTGAGCAGAGATGCCAGA-3′ 5′-TCCTTTGCATTGACATCAGC-3′
18S rRNA 101 5′-ATGCTCTTAGCTGAGTGTCCCG-3 5′-ATTCCTAGCTGCGGTATCCAGG-3
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HPR1 gene expression. Knockdown of BRAF expression in a BRAF-
mutated KAT-10 cell line by stable transfection of BRAF siRNA has
been previously reported [24]. RT-PCR analysis revealed that BRAF
knockdown reduced BRAF and HPR1 mRNA levels by 60% and
38%, respectively (Figure 3A). HPR1 enzymatic activity in the cell ly-
sates of BRAF siRNA–transfected KAT-10 cells was reduced by 30%
compared with that in control siRNA–transfected cells (Figure 3B).
However, the cell surface HS levels were dramatically increased in BRAF
siRNA–transfectedKAT 10 cells compared with that in control siRNA–
transfected KAT-10 cells (Figure 3C). These observations strongly sug-
gest that B-Raf kinase activation leads to increased HPR1 expression.
HPR1 Promoter Activity Is Decreased in BRAF-Suppressed
KAT-10 Cells
Our cotransfection experiment in Figure 1 suggests that mutant
BRAF or HRAS leads to increased HPR1 promoter activation. To cor-
roborate this observation, we tested whether HPR1 promoter activity
was decreased inBRAF-suppressedKAT-10 cells. The luciferase reporter
gene driven by a 0.3-, 0.7-, or 3.5-kb HPR1 promoter was introduced
into control or BRAF siRNA–transfected KAT-10 cells. As shown in
Figure 4, luciferase reporter gene expression driven by 0.3-, 0.7-, and
3.5-kb HPR1 promoter were at least two-fold higher in control than
BRAF siRNA–transfected KAT-10 cells. These observations suggest
that down-regulation of HPR1 gene expression in BRAF-suppressed
KAT-10 cells is mediated by suppression of HPR1 promoter activity.
Identification of a GABP-Binding Site as a Critical
cis-Responsive Element Responsible for BRAF-Induced
HPR1 Gene Expression
We and others have previous shown that several transcription factors,
mainly Sp1, the Ets family transcription factors, and Egr-1 (Figure 7)
play an important role in regulating basal and inducibleHPR1promoter
activity [12–16]. GABP, a member of the Ets family transcription fac-
tors, can be activated by B-Raf kinase. We tested whether elimination of
the Ets transcription factor binding site in the HPR1 promoter could
abrogate BRAF mutation–induced HPR1 promoter activity. A panel
of HPR1 promoter constructs with the ERE sites being mutated (Fig-
ure 5A) was introduced into control or BRAF siRNA–transfected KAT-
10 cells. Consistent with our previous observations [13], mutation of
any one of the four ERE sites significantly reduced HPR1 promoter ac-
tivity (Figure 5B). Luciferase gene expression driven by a 0.3-kb HPR1
promoter in control siRNA–transfected KAT-10 cells was about two-
fold higher than that in BRAF siRNA–transfected KAT-10 cells. Elim-
ination of any of the four ERE sites in this 0.3-kbHPR1 promoter led to
a comparable HPR1 promoter activity in control or in BRAF siRNA–
transfected KAT-10 cells. These observations suggest that the presence
of all ERE sites in the HPR1 promoter is required for mediating BRAF
mutation–induced HPR1 promoter activation.
To verify that BRAF mutation–inducedHPR1 gene expression is in-
deedmediated by theGABPbinding sites present in theHPR1promoter,
we tested whether luciferase reporter gene driven by a four-copy GABP
binding site is higher in control than in BRAF siRNA–transfected
KAT-10 cells. As shown in Figure 5C , there was no difference in the
luciferase activity in control and BRAF siRNA–transfected KAT-10
cells transfected with a pGL3/Basic reporter construct. However, lu-
ciferase gene expression driven by the 4×GABP binding site was al-
most two-fold higher in control than in BRAF siRNA–transfected
KAT-10 cells. This observation strongly suggests that the transcrip-
tional activity of the Ets family transcription factors is reduced in
BRAF-suppressed KAT-10 cells.
Down-regulation of GABPβ Expression in BRAF-Suppressed
KAT-10 Cells
Several Ets family transcription factors are upregulated in various
malignancies [32,33], probably because of oncogene mutation and ac-
tivation. Here we tested whether decreased HPR1 promoter activity in
BRAF-suppressed KAT-10 cells was due to decreased GABP expression
or activation. We first conducted immunofluorescence (IF) staining to
determine whether therewas a difference inGABPnucleus translocation
between control and BRAF-suppressed KAT-10 cells. As shown in
Figure 6A, bothGABPα and βwere extensively stained in the cytoplasm
and nuclei of control siRNA–transfected KAT-10 cells. The signals for
GABPβ but not GABPα were much weaker in both the cytoplasm
and nucleus in BRAF siRNA–transfected cells than in control siRNA–
transfected cells. To verify that GABPβ expression was downregulated
in BRAF-suppressed KAT-10 cells, Western blot analysis was conducted
to compare GABPα and β expression. GABPβwas expressed at a signifi-
cantly lower level in BRAF siRNA–transfected than in control siRNA–
transfected KAT-10 cells (Figure 6B). ERK phosphorylation and BRAF
expression were dramatically reduced in BRAF siRNA–transfected
KAT-10 cells compared with those in control siRNA–transfected
Figure 1. B-Raf kinase activation induces HPR1 expression. (A) In-
duction of HPR1 gene expression. HEK293 cells were transiently
transfected with the pEF6 empty vector or the vector encoding wild-
type BRAF, BRAFV600E, or HRASG12V. Total RNA was extracted and
analyzed for HPR1 mRNA expression by RT-PCR. (B) Induction of
HPR1 promoter–driven luciferase reporter gene expression. HEK293
cellswere cotransfectedwith the empty vector or the vector encoding
wild-type BRAF, BRAFV600E, or HRASG12V plus control luciferase re-
porter or the luciferase reporter gene driven by a 0.7- or 3.5-kb HPR1
promoter. pCMV/SPORT, which encodes a β-galactosidase gene,
was included as an internal control. After incubating for 48 hours,
the cells were harvested and analyzed for luciferase activity. The rela-
tive luciferase activity was calculated. One representative example in
triplicate from three experiments with similar results is presented.
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Figure 2. B-Raf kinase activation induces cell surface HS degradation. (A) HEK293 cells transiently transfected with the indicated vectors.
After incubating for 48 hours, the cells were harvested and analyzed for cell surface HS levels by FACS. (B) HPR1 inhibitors restored cell
surface HS levels. Cells transiently transfected with the empty vector or the vector encoding BRAFV600E or HRASG12V in the absence or pres-
ence of PI-88 or heparin (50 μg/ml) for 48 hours were analyzed for cell surface HS levels by FACSwith anti-HS mAb. Green line indicates IgM
control; red line, anti-HS mAb.
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KAT-10 cells. The levels of Sp1, Sp3, total ERK, and Egr-1 expression
were not reduced or were only marginally reduced in BRAF siRNA–
transfected KAT-10 cells. To further verify the reduction of GABPβ in
BRAF siRNA–transfected cells, we conducted real-time RT-PCR and
found that GABPβ mRNA levels were 30% lower in BRAF siRNA–
transfected cells than in control siRNA–transfected KAT-10 cells.
However, there was no difference in GABPα mRNA levels between
BRAF siRNA– and control siRNA–transfected KAT-10 cells. These ob-
servations suggest that suppression of BRAF expression leads to down-
regulation of GABPβ expression, subsequently leading to decreased
HPR1 promoter activation and gene expression.
Discussion
The molecular mechanisms of increased HPR1 expression in a variety
of malignancies are poorly understood. Increased HPR1 expression in
prostate and bladder cancers is mediated by increased Egr-1 expression
and HPR1 promoter hypomethylation [16,17]. p53 mutation may also
contribute to increased HPR1 expression because wild-type p53 can
negatively regulate HPR1 expression [18]. In the present study, we
provide several lines of evidence that RAS or BRAF gene mutations
are responsible for increased HPR1 expression: 1) mutant RAS or BRAF
genes were able to directly activate the HPR1 promoter and to induce
HPR1 gene expression; 2) increased HPR1 expression in mutant BRAF
or RAS-transfected HEK293 cells led to the loss of cell surface HS,
which could be blocked by two HPR1 inhibitors; 3) knockdown of
BRAF gene expression in BRAF-mutated KAT-10 cells led to decreased
HPR1 expression and increased cell surface HS levels; and 4) mecha-
nistic studies demonstrated that GABP, a critical transcription factor
involved in regulatingHPR1 gene expression, was downregulated when
BRAF expression was suppressed. These observations collectively sug-
gest that increased HPR1 expression in a wide range of tumors could be
caused in part by mutation of oncogenes such as BRAF, RAS, or their
upstream growth factor receptors such as EGFR (Figure 7).
The Ets transcription factor family has more than 30 members that
bind to the coreDNA sequence GGA(A/T). GABP is a uniquemember
of the Ets family because its α and β subunits form a heterodimer
complex that often binds tandem ERE sites separated by approximately
10 to 30 bp. A recent genome-wide GABP occupancy study indicates
that many GABP binding locations contain two ERE sites [34]. There
are two sets of tandem ERE sites within the proximal region of the
HPR1 promoter (Figure 7) [13]. Mutation of any one of the ERE sites
should eliminate the binding of GABP to one set of tandem ERE sites.
In addition, GABP cooperates with its neighboring Sp1, so that dis-
ruption of one set of GABP binding site leads to a significant reduction
Figure 3. BRAF gene knockdown leads to decreased HPR1 expression and increased cell surface HS levels. (A) Real-time RT-PCR analysis
of HPR1 and BRAFmRNA. Total RNA was extracted from KAT-10 cells and analyzed for HPR1 and BRAFmRNA by real-time RT-PCR. One
of two experiments in triplicate with similar results is shown. (B) HPR1 enzymatic activity. Cell lysates of KAT-10 cells transfected with
control or BRAF siRNA were analyzed for HPR1 activity by ELISA. (C) FACS analysis of the cell surface HS levels. Single cell suspensions
of KAT-10 cells transfected with control or BRAF siRNA were analyzed for cell surface HS levels by FACS. Black line indicates IgM control;
green line, anti-HS mAb.
Figure 4. Decreased HPR1 promoter activity in BRAF siRNA–
transfected KAT-10 cellls. Control or BRAF siRNA–transfected KAT-
10 cells were transiently transfected with the luciferase reporter
gene expression driven by a 0.3-, 0.7-, or 3.5-kb HPR1 promoter.
pGL3/Basic luciferase reporter construct was included as a negative
control. After incubating for 48 hours, the cells were harvested and
analyzed for luciferase activity.
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Figure 5. Evidence that the GABP binding site in the HPR1 promoter is critical for BRAF-mediated HPR1 gene regulation. (A) Schematic
illustration of a panel of the HPR1 promoter–driven luciferase reporter constructs. ERE sites marked with a cross sign denote those with
altered nucleotides can no longer be bound by Ets transcription factors. (B) Control or BRAF siRNA–transfected KAT-10 cells were transiently
transfected with the luciferase reporter constructs as shown in (A) or with 4×GABP binding site–driven luciferase reporter construct (C).
After incubating for 48 hours, the cells were harvested and analyzed for luciferase activity.
Figure 6. Down-regulation of GABPβ in BRAF-suppressed KAT-10 cells. (A) IF staining of GABPα and β. Control or BRAF siRNA–transfected
KAT-10 cells were stained with an anti-GABPα and β rabbit IgG, followed by staining with fluorescein-conjugated goat antirabbit IgG. A
normal rabbit antiserum was included as a negative control. No nonspecific signal was presented (photograph not shown). (B) Western
blot analyses of the signaling molecules and transcription factors involved in regulating HPR1 gene expression. Cell lysates from control
or BRAF siRNA–transfected KAT-10 cells were analyzed for the expression of several transcription factors and signaling molecules by their
specific antibodies. (C) Real-time RT-PCR analyses of GABPα and β expression. Total RNA was extracted from KAT-10 cells transfected with
BRAF or control siRNA expression vector and analyzed for GABPα and β by real-time RT-PCR. One of two experiments in triplicate with
similar results is shown.
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of HPR1 promoter activity [13]. This may partially explain that,
although one set of the GABP binding sites in the HPR1 remains
functional, there was no significant difference in luciferase reporter gene
expression driven by theHPR1 promoter in control and BRAF siRNA–
transfected KAT-10 cells.
GABP is one of the transcription factors that are involved in regulat-
ing HPR1 gene expression [13]. Our present study demonstrates that
GABPβ expression was downregulated in BRAF-suppressed KAT-10
cells, as analyzed by Western blot and real-time RT-PCR. IF staining
revealed that the signals for GABPβ expression were reduced in both
cytoplasm and nucleus. It is likely that the reduced presence of GABPβ
in nucleus may not be due to its inability to translocate into nucleus.
Nevertheless, because the HPR1 promoter– and 4×GABP binding
site–driven luciferase reporter gene expression was significantly lower
in BRAF siRNA than in control siRNA–transfected KAT-10 cells, this
suggests that GABP plays an important role in mediating mutant
BRAF-induced HPR1 expression. It should be noted that BRAF gene
mutation may induce the expression of other Ets family members that
also contribute to HPR1 expression. For example, activation of the
MAP kinase pathway leads to increased Ets2 expression and phosphory-
lation, subsequently leading to increased matrix metalloproteinase 9 ex-
pression [35–37].
Previous studies have shown that GABP can be phosphorylated by
Raf-1 kinase [38,39]. Fromm and Burden [40] showed that GABPα
can be phosphorylated at threonine 280 and activated by ERK and
JNK kinases in neuregulin-1–stimulated muscle cells. However, a re-
cent study suggests that GABPα phosphorylation is not essential for
neuregulin-1–induced acetylcholine receptor expression [41]. Although
it is likely that MAP kinase activation due to BRAF gene mutation may
lead to increased phosphorylation of GABPα, increased GABPβ expres-
sion in BRAF-mutated cell lines may play a dominant role in mediating
BRAF mutation–induced HPR1 expression.
It has been well documented that several transcription factors of the
Ets family, in particular Ets-1, Ets-2, and PEA, are overexpressed in a
variety of malignancies such as breast and ovarian cancers. GABP is
ubiquitously expressed in normal tissues. GABP plays a critical role
in regulating the expression of BRCA1 and prolactin, both of which
are involved in tumorigenesis [42–44]. Our present study suggests
the possibility that GABPβ expression can be upregulated in a variety
of cancers due to the activation of the MAP kinase pathway. GABP
and Sp1, another housekeeping transcription factor that is upregulated
in a variety of cancers [45], can cooperate to induce HPR1 expression
in cancer (Figure 7). Egr-1 is another transcription factor involved in
regulating HPR1 gene expression [12–15]. Egr-1 overexpression in
cancer may also contribute to increased HPR1 expression (Figure 7).
Our present study shows that there was no significant difference in
Sp1 and Egr-1 expression in control and BRAF siRNA–transfected
KAT-10 cells. In addition, when the GABP binding sites in the
HPR1 promoter were mutated, there was no difference in luciferase
gene expression in control or BRAF siRNA vector–transfected KAT-
10 cells. These observations suggest that Sp1 and Egr-1 do not contrib-
ute to mutant B-Raf kinase–mediated increase of HPR1 expression. Be-
cause we did not analyze the expression of other Ets family member, it
remains unknown if other Ets transcript factors may also required for
mutant BRAF–induced HPR1 expression.
BRAF-mutated thyroid cancers and melanomas tend to be more
aggressive than those without BRAF mutation [19,46]. B-Raf kinase
activation due to the BRAF gene mutations leads to the up-regulation
of several molecules that are involved in tumor metastasis [19,46]. For
example, BRAFV600E mutation has been shown to regulate melanoma
Figure 7. Signaling pathway and transcription factors involved in HPR1 gene expression in cancer. Mutations and/or overexpression of the
growth factor receptor genes such as EGFR and its downstream signaling molecules such as RAS and BRAF genes result in increased
expression and/or translocation of the Ets family transcription factors such as GABP and Ets-1. These transcription factors in cooperation
with several other transcription factors overexpressed in cancer, such as Sp1 and Egr-1, lead to HPR1 expression in cancer. HPR1 promoter
demethylation and p53 mutations also contribute to increased HPR1 gene expression (not shown).
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metastasis by increasing fibronectin expression and by promoting inter-
action of melanoma cells with neutrophils to facilitate extravasation
across the endothelial cell lining as well as enhancing proliferation in
the lung microenvironment [47,48]. Inhibition of these processes
leads to a decrease of lung metastasis of BRAF-mutated melanoma cells
by four- to five-fold [49]. BRAF gene mutation also leads to the up-
regulation of matrix metalloproteinase expression in thyroid cancer
and melanoma [50,51]. Our present study demonstrates that BRAF
mutation led to up-regulation of HPR1, an endoglycosidase that is
involved in tumor angiogenesis and metastases. This observation is
consistent with a prior study showing that sorafenib, an inhibitor of
B-Raf kinase and other growth factor receptor, blocks vascular devel-
opment in malignant melanomas in a xenograft model [52]. It is antici-
pated that sorafenib treatment may lead to a significant decrease in
HPR1 expression, subsequently suppressing tumor angiogenesis. These
studies collectively suggest that up-regulation of HPR1 and other
molecules due to BRAF gene mutation may act in concert to promote
tumor angiogenesis and metastases.
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